Centene Corporation
CNC
$68.29
+1.40%
Centene Corporation is a managed care organization specializing in government-sponsored healthcare plans, including Medicaid, Medicare, and individual exchange plans, serving approximately 20 million medical members as of December 2025. As one of the largest Medicaid managed care providers in the United States, Centene distinguishes itself through its deep focus on government-sponsored programs, with Medicaid comprising about 64% of its membership. The current investor narrative centers on the company's strategic pivot toward profitability amid a membership slump in its Affordable Care Act business, as evidenced by recent staff buyouts and cost-cutting measures, while a favorable Medicare Advantage payment increase from CMS has provided a tailwind for the broader managed care sector.…
CNC
Centene Corporation
$68.29
Related headlines
Investment Opinion: Should I buy CNC Today?
Rating: Hold. Centene offers a compelling deep-value proposition with a 0.10x PS ratio and $4.3 billion in free cash flow, but the persistent net losses and neutral analyst consensus warrant caution. The average analyst EPS estimate of $9.00 implies a forward PE of 7.5x, which is attractive if achieved, but the lack of bullish ratings tempers enthusiasm.
Supporting Evidence: The primary valuation metric, PS ratio of 0.10x, is near historical lows and well below industry averages. Revenue growth of 21.9% YoY in Q4 2025 demonstrates top-line momentum. Free cash flow of $4.3 billion TTM provides a cushion, and the forward PE of 7.5x based on analyst estimates suggests significant earnings recovery is priced in. However, the negative trailing PE and -33.4% ROE highlight the current earnings distress.
Risks & Conditions: The biggest risks are margin deterioration and membership losses in the ACA business. This Hold would upgrade to Buy if the company reports a profitable quarter with positive operating margin, or if analysts upgrade the stock. It would downgrade to Sell if net losses widen or free cash flow turns negative. Overall, Centene appears undervalued relative to its revenue and cash flow, but fairly valued relative to its earnings uncertainty.
Sign up to view all
CNC 12-Month Price Forecast
Centene's outlook is balanced between deep value and earnings distress. The low PS ratio and strong cash flow provide a margin of safety, but the lack of profitability and neutral analyst sentiment limit upside. The base case of gradual improvement is most likely, with a 50% probability. A bullish outcome would require a clear path to profitability, while a bearish outcome could materialize if losses deepen. The stance is neutral with medium confidence, as the stock's momentum is strong but fundamentals are still weak.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Centene Corporation's 12-month outlook, with a consensus price target around $88.78 and implied upside of +30.0% versus the current price.
Average Target
$88.78
5 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
5
covering this stock
Price Range
$55 - $89
Analyst target range
Centene has coverage from 5 analysts, with a consensus recommendation leaning neutral (no explicit breakdown provided, but ratings from JP Morgan, Mizuho, Morgan Stanley, and Wells Fargo are all Neutral/Equal Weight). The average estimated EPS for the upcoming period is $9.00, with a range of $8.72 to $9.28. The average revenue estimate is $214.99 billion, implying significant growth from current levels. The implied upside to the average target cannot be calculated without a target price, but the EPS estimates suggest a forward PE of 7.5x at the current price of $67.35, which is attractive if achieved. The range of EPS estimates is relatively narrow (low $8.72, high $9.28), indicating moderate conviction among analysts. Recent ratings actions show no upgrades or downgrades, with firms maintaining neutral stances. The lack of strong bullish sentiment suggests that analysts are waiting for clearer signs of earnings recovery. The limited coverage (5 analysts) is typical for a large-cap stock, but the neutral consensus reflects the uncertainty around Centene's turnaround.
Bulls vs Bears: CNC Investment Factors
Centene presents a classic deep-value turnaround story with compelling upside if profitability is restored, but significant execution risk remains. The bull case rests on a 0.10x PS ratio, strong revenue growth, and positive free cash flow, while the bear case highlights persistent net losses, margin deterioration, and a neutral analyst consensus. The single most important tension is whether Centene can convert its revenue scale into sustainable profitability—if it does, the stock could re-rate substantially; if losses continue, the deep discount may prove to be a value trap. Currently, the evidence slightly favors the bull case given the cash flow strength and low valuation, but the margin trajectory demands close monitoring.
Bullish
- Deep Value PS Ratio: Centene trades at a PS ratio of 0.10x, near its historical low and well below the industry average. This suggests the market is pricing in significant pessimism, offering a potential value opportunity if earnings recover.
- Strong Revenue Growth: Q4 2025 revenue grew 21.9% YoY to $49.7 billion, driven by Medicaid and Commercial segments. This top-line momentum provides a base for future profitability improvements.
- Positive Free Cash Flow: Despite net losses, Centene generated $4.3 billion in TTM free cash flow, indicating that non-cash charges (e.g., reserves) are distorting earnings. Cash flow supports debt service and strategic investments.
- Favorable Medicare Tailwind: A larger-than-expected 2027 Medicare Advantage payment increase from CMS provides revenue visibility and margin support for the managed care sector, benefiting Centene's Medicare segment.
Bearish
- Persistent Net Losses: Centene reported net losses in three of the last four quarters, including -$1.1 billion in Q4 2025. TTM EPS is -$2.24, and ROE is -33.4%, signaling deep profitability issues.
- Membership Slump in ACA: A significant loss in Affordable Care Act membership has forced staff buyouts, pressuring near-term revenue and signaling competitive or pricing challenges in the exchange business.
- Deteriorating Margins: Gross margin fell to 15.2% in Q4 2025 from 16.4% in Q3 2025, and operating margin was -3.5%. The net margin of -2.2% indicates cost structure issues that may persist.
- Neutral Analyst Consensus: All five covering analysts rate Centene as Neutral/Equal Weight, with no upgrades. The average EPS estimate of $9.00 implies a forward PE of 7.5x, but the lack of bullish ratings suggests skepticism about the turnaround.
CNC Technical Analysis
Centene's stock is in a powerful recovery uptrend, with a 1-year price change of +107.1% as of July 10, 2026. The current price of $67.35 sits at 97.2% of its 52-week range ($25.08 low to $69.29 high), indicating the stock is near its highs and reflecting strong momentum. This positioning near the top of the range suggests bullish sentiment and potential overextension, but also signals that the market is pricing in continued positive fundamentals. Short-term momentum is accelerating, with a 1-month change of +3.1% and a 3-month change of +80.6%, the latter dramatically outpacing the 1-year trend. The 3-month surge from a low of $31.80 in late March to current levels represents a sharp reversal from the stock's earlier downtrend, confirming a strong recovery. The 1-month change is more modest, suggesting a potential consolidation phase after the rapid ascent. The stock's beta of 1.077 indicates slightly higher volatility than the market, but not extreme. Key support lies at the 52-week low of $25.08, while resistance is at the 52-week high of $69.29. A breakout above $69.29 would signal a continuation of the uptrend, while a breakdown below recent support near $60 could indicate a pullback. The stock's relative strength over 3 months (69.45 vs. SPY's 11.11%) underscores its outperformance.
Beta
1.08
1.08x market volatility
Max Drawdown
-55.5%
Largest decline past year
52-Week Range
$25-$69
Price range past year
Annual Return
+117.2%
Cumulative gain past year
| Period | CNC Return | S&P 500 |
|---|---|---|
| 1m | +4.8% | +1.0% |
| 3m | +83.3% | +7.9% |
| 6m | +47.9% | +8.5% |
| 1y | +117.2% | +20.1% |
| ytd | +63.5% | +9.9% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
CNC Fundamental Analysis
Centene's revenue trajectory shows strong growth, with Q4 2025 revenue of $49.725 billion, up 21.9% year-over-year from $40.805 billion in Q4 2024. However, the company has experienced significant net losses in recent quarters: Q4 2025 net income was -$1.1 billion, following -$6.631 billion in Q3 2025 and -$253 million in Q2 2025, compared to a profit of $1.311 billion in Q1 2025. The revenue growth is driven by the Medicaid segment ($37.653 billion) and Commercial segment ($10.792 billion), but the losses reflect elevated costs and reserve charges. Profitability metrics are weak, with a gross margin of 15.2% in Q4 2025, down from 16.4% in Q3 2025 and 9.1% in Q4 2024. The net margin was -2.2% in Q4 2025, and the operating margin was -3.5%. The company has been unprofitable on a trailing twelve-month basis, with EPS of -$2.24 in Q4 2025. However, free cash flow generation remains positive at $4.321 billion TTM, indicating that non-cash charges are driving the accounting losses. Centene's balance sheet shows a debt-to-equity ratio of 0.94 and a current ratio of 1.68, indicating adequate liquidity. The company generated $437 million in operating cash flow in Q4 2025 and $224 million in free cash flow, though this was down from $1.785 billion in Q2 2025. ROE is negative at -33.4%, reflecting the net losses, but the company's cash position of $17.888 billion provides a buffer.
Quarterly Revenue
$49.7B
2025-12
Revenue YoY Growth
+21.9%
YoY Comparison
Gross Margin
15.2%
Latest Quarter
Free Cash Flow
$4.3B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is CNC Overvalued?
Given that Centene's trailing twelve-month net income is negative (EPS -$2.24), the price-to-sales (PS) ratio is the most appropriate valuation metric. The current PS ratio is 0.10x, based on a market cap of $20.2 billion and TTM revenue of approximately $194.8 billion. The forward PE ratio of 15.05x is available but less relevant due to current losses; the gap between the negative trailing PE and positive forward PE implies the market expects a return to profitability. Compared to the healthcare plans industry, Centene's PS ratio of 0.10x is significantly below the industry average (data not provided, but typically above 0.5x for profitable peers). This deep discount reflects the company's recent losses and uncertainty around earnings recovery. Historically, Centene's PS ratio has ranged from about 0.4x to 1.5x over the past five years, with the current 0.10x near the bottom of that range. This suggests the market is pricing in pessimistic expectations, potentially offering value if the company can restore profitability. The price-to-book ratio of 1.01x is also near historical lows, further supporting a value thesis.
PE
-3.0x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range -72x~220x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
-4.1x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: Centene's primary financial risk is its inability to generate consistent net income, with TTM net losses of -$2.24 per share and a negative ROE of -33.4%. The company's gross margin has declined to 15.2% in Q4 2025 from 16.4% in Q3 2025, and operating margin is -3.5%, indicating cost pressures. While free cash flow of $4.3 billion TTM provides a buffer, the reliance on non-cash adjustments to achieve positive cash flow raises questions about earnings quality. The debt-to-equity ratio of 0.94 is manageable, but interest expense of $168 million per quarter adds to the earnings drag.
Market & Competitive Risks: Centene's valuation at 0.10x PS is a deep discount, but this also reflects market skepticism about its ability to compete effectively in the ACA exchanges, where membership is slumping. The stock's beta of 1.077 indicates slightly above-market volatility, and the recent 107% rally means any negative catalyst could trigger profit-taking. Regulatory risk is elevated given the company's dependence on government programs (Medicaid, Medicare, ACA), and changes in funding or policy could materially impact revenue. The neutral analyst consensus (all Equal Weight) suggests limited near-term upside conviction.
Worst-Case Scenario: If Centene fails to reverse its membership losses and margins continue to compress, the stock could retest its 52-week low of $25.08, representing a 62.8% decline from the current price of $67.35. This scenario would likely involve further net losses, a credit rating downgrade, and a loss of investor confidence. The historical max drawdown of -55.5% provides a reference for the potential downside severity.
FAQ
The primary risk is earnings distress: Centene has a TTM net loss of -$2.24 per share and negative ROE of -33.4%, with margins under pressure. Second, membership risk: a slump in ACA enrollment has forced staff buyouts, threatening revenue. Third, regulatory risk: dependence on government programs (Medicaid, Medicare) makes it vulnerable to policy changes. Fourth, valuation risk: at 97% of its 52-week high, the stock is vulnerable to profit-taking, especially given its beta of 1.077. The most severe risk is a continued loss cycle that could drive the stock back to $25.08.
The 12-month forecast is mixed. The base case (50% probability) sees the stock trading between $65 and $75, supported by gradual margin improvement and a forward PE of 7.5x. The bull case (25% probability) targets $75-$85, driven by a return to profitability and analyst upgrades. The bear case (25% probability) sees the stock falling to $30-$45 if losses persist. The most likely scenario is the base case, assuming Centene stabilizes margins and meets analyst EPS estimates of $9.00. The stock's recent momentum is strong, but sustainability depends on earnings execution.
Centene appears undervalued based on revenue and cash flow metrics, but overvalued relative to current earnings. The PS ratio of 0.10x is near a five-year low and well below the industry average, suggesting the market is pricing in significant distress. The price-to-book ratio of 1.01x also indicates a discount to book value. However, the trailing PE is negative due to losses, and the forward PE of 7.5x depends on achieving analyst EPS estimates. The valuation implies the market expects a return to profitability, but the deep discount already reflects high uncertainty.
Centene is a speculative buy for value-oriented investors willing to bet on a turnaround. The stock trades at a deep 0.10x PS ratio, near its historical low, and analysts expect EPS of $9.00, implying a forward PE of 7.5x. However, the company has posted net losses in three of the last four quarters, and all five analysts rate it Neutral. The risk/reward is attractive if profitability improves, but the stock could fall 62% to its 52-week low if losses persist. It is not a good buy for conservative investors or those seeking stable income.
Centene is better suited for medium-term investment (12-24 months) given its turnaround nature. Short-term trading is risky due to high volatility (beta 1.077) and the stock's proximity to its 52-week high. Long-term holding is speculative because the company's profitability track record is inconsistent, and it pays no dividend. A concrete minimum holding period of 12 months is recommended to allow time for margin improvement and earnings recovery to materialize. Investors should monitor quarterly results closely for signs of a sustainable turnaround.